(S)-1-(Pent-4′-enoyl)-4-(hydroxymethyl)-azetidin-2-one derivatives as inhibitors of human fatty acid amide hydrolase (hFAAH): synthesis, biological evaluation and molecular modelling

References

• Pillarisetti S, Alexander CW, Khanna I. Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases. Drug Discov Today 2009;14:1098–111
   PubMed Web of Science ®Google Scholar
• Gerra G, Zaimovic A, Gerra ML, et al. Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent Pat CNS Drug Discov 2010;5:46–52
   PubMedGoogle Scholar
• Muccioli GG. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 2010;15:474–83
   PubMed Web of Science ®Google Scholar
• Vandevoorde S, Lambert DM. The multiple pathways of endocannabinoid metabolism: a zoom out. Chem Biodivers 2007;4:1858–81
   PubMed Web of Science ®Google Scholar
• Vandevoorde S. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem 2008;8:247–67
   PubMed Web of Science ®Google Scholar
• Seierstad M, Breitenbucher JG. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem 2008;51:7327–43
   PubMed Web of Science ®Google Scholar
• Bertrand T, Augé F, Houtmann J, et al. Structural basis for human monoglyceride lipase inhibition. J Mol Biol 2010;396:663–73
   PubMed Web of Science ®Google Scholar
• Feledziak M, Lambert DM, Marchand-Brynaert J, et al. Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid’s activity by preventing their hydrolysis. Rec Patents CNS Drug Disc 2012;7:49–70
   PubMedGoogle Scholar
• Bisogno T, Maccarone M. Latest advances in the discovery of fatty acid amide hydrolase inhibitors. Expert Opin Drug Discov 2013;8:509–22
   PubMed Web of Science ®Google Scholar
• Khanna IK, Alexander CW. Fatty acid amide hydrolase inhibitors – progress and potential. CNS Neurol Disord Drug Targets 2011;10:545–58
   PubMed Web of Science ®Google Scholar
• Bracey MH, Hanson MA, Masuda KR, et al. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 2002;298:1793–6
   PubMed Web of Science ®Google Scholar
• Mc Kinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005;74:411–32
   PubMed Web of Science ®Google Scholar
• Michaux C, Labar G. Fatty acid amide hydrolase: from characterization to therapeutics. Chem Biodivers 2007;4:1882–902
   PubMed Web of Science ®Google Scholar
• Mileni M, Johnson DS, Wang Z, et al. Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci USA 2008;105:12820–4
   PubMed Web of Science ®Google Scholar
• Mileni M, Garfunkle J, DeMartino JK, et al. Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by α-ketoheterocycle inhibitors revealed from cocrystal structures. J Am Chem Soc 2009;131:10497–506
   PubMed Web of Science ®Google Scholar
• Mileni M, Garfunkle J, Ezzili C, et al. X-ray crystallographic analysis of α-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J Med Chem 2010;53:230–40
   PubMed Web of Science ®Google Scholar
• Mileni M, Kamtekar S, Wood DC, et al. Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. J Mol Biol 2010;400:743–54
   PubMed Web of Science ®Google Scholar
• Labar G, Bauvois C, Borel F, et al. Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling. ChemBioChem 2010;11:218–27
   PubMed Web of Science ®Google Scholar
• Ortar G, Bisogno, T, Ligresti A, et al. Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem 2008;51:6970--9
   PubMed Web of Science ®Google Scholar
• Bisogno T, Ortar G, Petrosino S, et al. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim Biophys Acta 2009;1791:53–60
   PubMed Web of Science ®Google Scholar
• Urbach A, Muccioli GG, Stern E, et al. 3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett 2008;18:4163–7
   PubMed Web of Science ®Google Scholar
• Böttcher T, Sieber SA. β-Lactones as privileged structures for the active-site labeling of versatile bacterial enzyme classes. Angew Chem Int Ed 2008;47:4600–3
   PubMed Web of Science ®Google Scholar
• Gérard S, Nollet G, Vande Put J, et al. 1-Alkoxycarbonyl-3-halogenoazetidin-2-ones as elastase (PPE) inhibitors. Bioorg Med Chem 2002;10:3955–64
   PubMed Web of Science ®Google Scholar
• Gérard S, Galleni M, Dive G, et al. Synthesis and evaluation of N1/C4-substituted β-lactams as PPE and HLE inhibitors. Bioorg Med Chem 2004;12:129–38
   PubMed Web of Science ®Google Scholar
• Gerona-Navarro G, Perez de Vega MJ, Garcia-Lopez MT, et al. Synthesis and anti-HCMV activity of 1-acyl-β-lactams and 1-acylazetidines derived from phenylalanine. Bioorg Med Chem Lett 2004;14:2253–6
   PubMed Web of Science ®Google Scholar
• Gerona-Navarro G, Perez de Vega MJ, Garcia-Lopez MT, et al. From 1-acyl-β-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors. J Med Chem 2005;48:2612–21
   PubMed Web of Science ®Google Scholar
• Marchand-Brynaert J, Brulé C. Penicillins. In: Katritzky AR, Ramsden CA, Scriven EFV, Taylor RJK, eds. Comprehensive heterocyclic chemistry III. Vol. 2. Oxford: Elesvier Ltd; 2008:173–237
   Google Scholar
• Feledziak M, Michaux C, Urbach A, et al. β-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase. J Med Chem 2009;52:7054–68
   PubMed Web of Science ®Google Scholar
• Berks AH. Preparations of two pivotal intermediates for the synthesis of 1-β-methyl carbapenem antibiotics. Tetrahedron 1996;52:331–75
   Web of Science ®Google Scholar
• Urbach A, Dive G, Marchand-Brynaert J. Novel large-ring 1,3-bridged 2-azetidinones as potential inhibitors of penicillin-binding proteins. Eur J Org Chem 2009;11:1757–70
   Web of Science ®Google Scholar
• Salzman TN, Ratcliffe RW, Christensen BG, Bouffard FA. A stereocontrolled synthesis of (+)-thienamycin. J Am Chem Soc 1980;102:6161–3
   Web of Science ®Google Scholar
• Baldwin JE, Adlington RM, Callins DW, et al. Stereospecific synthesis of dealanylalahopcin. Tetrahedron 1990;46:4733–48
   Web of Science ®Google Scholar
• Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727–48
   PubMed Web of Science ®Google Scholar
• Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 09, Revision A.02. Wallingford (CT): Gaussian, Inc.; 2009
   Google Scholar
• De Lano WL. The PyMOL molecular graphics system, 0.99. San Carlos: DeLano Scientific; 2002
   Google Scholar
• Gérard S, Marchand-Brynaert J. Protecting group migration in the chemistry of 1-t-butyldimethylsilyl-4-hydroxymethyl-2-azetidinone. Tetrahedron Lett 2003;44:6339–42
   Web of Science ®Google Scholar
• Feledziak M, Muccioli GG, Lambert DM, et al. SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process. J Med Chem 2011;54:6812–23
   PubMed Web of Science ®Google Scholar
• Feledziak M, Michaux C, Lambert DM, et al. An unprecedented reversible mode of action of β-lactams for the inhibition of human fatty acid amide hydrolase (hFAAH). Eur J Med Chem 2013;60:101–11
   PubMed Web of Science ®Google Scholar
• Klein SI, Molino BF, Czekaj M, et al. Design of a new class of orally active fibrinogen receptor antagonists. J Med Chem 1998;41:2492–502
   PubMed Web of Science ®Google Scholar
• Menghin S, Pertz HH, Kramer K, et al. Nα-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H1-receptor agonists. J Med Chem 2003;46:5458–70
   PubMed Web of Science ®Google Scholar
• Gérard S, Dive G, Clamot B, et al. Synthesis, hydrolysis, biochemical and theoretical evaluation of 1,4-bis(alkoxycarbonyl)azetidin-2-ones as potential elastase inhibitors. Tetrahedron 2002;58:2423–33
   Web of Science ®Google Scholar
• Labar G, Vliet FV, Wouters J, et al. A MBP-FAAH fusion protein as a tool to produce human and rat fatty acid amide hydrolase: expression and pharmacological comparison. Amino Acids 2008;34:127–33
   PubMed Web of Science ®Google Scholar
• Labar G, Bauvois C, Muccioli GG, et al. Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling. ChemBioChem 2007;8:1293–7
   PubMed Web of Science ®Google Scholar
• Mileni M, Garfunkle J, Ezzili C, et al. Fluoride-mediated capture of a noncovalent bound state of a reversible covalent enzyme inhibitor: X-ray crystallographic analysis of an exceptionally potent α-ketoheterocycle inhibitor of fatty acid amide hydrolase. J Am Chem Soc 2011;133:4092–100
   PubMed Web of Science ®Google Scholar
• Verdonk ML, Chessari G, Cole JC, et al. Modeling water molecules in protein-ligand docking using GOLD. J Med Chem 2005;48:6504–15
   PubMed Web of Science ®Google Scholar
• Huang W, Gherib R, Gauld JW. An active site water broadens substrate specificity in S-ribosylhomocysteinase (LuxS): a docking, MD, and QM/MM study. J Phys Chem B 2012;116:8916–29
   PubMed Web of Science ®Google Scholar
• Yoshikawa Y, Kobayashi K, Oishi S, et al. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions. Bioorg Med Chem Lett 2012;22:2146–50
   PubMed Web of Science ®Google Scholar
• Otrubova K, Boger DL. α-Ketoheterocycle-based inhibitors of fatty acid amide hydrolase (FAAH). ACS Chem. Neuroscience 2012;3:340–8
   PubMed Web of Science ®Google Scholar
• Estiarte MA, Johnson RJ, Kaub CJ, et al. 2-Amino-5-arylbenzoxazole derivatives as potent inhibitors of fatty acid amide hydrolase (FAAH). MedChemComm 2012;3:611–19
   Web of Science ®Google Scholar
• Tian G, Paschetto KA, Gharahdaghi F, et al. Mechanism of inhibition of fatty acid amide hydrolase by sulfonamide-containing benzothiazoles: long residence time derived from increased kinetic barrier and not exclusively from thermodynamic potency. Biochemistry 2011;50:6867–78
   PubMed Web of Science ®Google Scholar
• Min X, Thibault ST, Porter AC, et al. Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH). Proc Natl Acad Sci USA 2011;108:7379–84
   PubMed Web of Science ®Google Scholar
• Gowlugari S, DeFalco J, Nguyen MT, et al. Discovery of potent, non-carbonyl inhibitors of fatty acid amide hydrolase (FAAH). MedChemComm 2012;3:1258–63
   Web of Science ®Google Scholar
• Caprioli A, Coccurello R, Rapino C, et al. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models. J Pharmacol Exper Therapeutics 2012;342:188–95
   PubMed Web of Science ®Google Scholar
• Ezzili C, Mileni M, McGlinchey N, et al. Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: orally active, long-acting analgesics. J Med Chem 2011;54:2805–22
   PubMed Web of Science ®Google Scholar
• Swinney DC, Anthony J. How were new medicines discovered? Nature Rev Drug Discov 2011;10:507--19
   PubMed Web of Science ®Google Scholar
• Kumar K, Waldmann H. Synthesis of natural product inspired compound collections. Angew Chem Int Ed 2009;48:3224–42
   PubMed Web of Science ®Google Scholar